Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile

被引：6
作者：
Crawford, ED [1 ]
机构：
[1] Univ Colorado, Hlth Sci Ctr, Aurora, CO 80010 USA
来源：
BJU INTERNATIONAL | 2005年 / 95卷
关键词：
LUTS; BPH; alpha(1)-adrenoceptor antagonists; 5 alpha-reductase inhibitors; efficacy; tolerability; disease progression;
D O I：
10.1111/j.1464-410X.2005.05484.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1 / 5
页数：5
相关论文
共 30 条
[1]   The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society (Reprinted from Neurourology and Urodynamics, vol 21, pg 167-178, 2002) [J].
Abrams, P ;
Cardozo, L ;
Fall, M ;
Griffiths, D ;
Rosier, P ;
Ulmsten, U ;
Van Kerrebroeck, P ;
Victor, A ;
Wein, A .
UROLOGY, 2003, 61 (01) :37-49
[2]   Integrating the patient risk profile in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) [J].
Artibani, W .
EUROPEAN UROLOGY SUPPLEMENTS, 2004, 3 (04) :1-6
[3]   Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia [J].
Auerbach, SM ;
Gittelman, M ;
Mazzu, A ;
Cihon, F ;
Sundaresan, P ;
White, WB .
UROLOGY, 2004, 64 (05) :998-1003
[4]   Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system [J].
Barendrecht, MM ;
Koopmans, RP ;
De La Rosette, JJMCH ;
Michel, MC .
BJU INTERNATIONAL, 2005, 95 :19-28
[5]  
*CDER, CDER NEW GEN DRUG AP
[6]   Introduction and concluding remarks [J].
Chapple, CR .
EUROPEAN UROLOGY, 1999, 36 :1-6
[7]   THE PREVALENCE OF PROSTATISM - A POPULATION-BASED SURVEY OF URINARY SYMPTOMS [J].
CHUTE, CG ;
PANSER, LA ;
GIRMAN, CJ ;
OESTERLING, JE ;
GUESS, HA ;
JACOBSEN, SJ ;
LIEBER, MM .
JOURNAL OF UROLOGY, 1993, 150 (01) :85-89
[8]  
Coffey DS, 1998, BRIT J UROL, V81, P1
[9]   Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms [J].
De La Rosette, JJMCH ;
Kortmann, BBM ;
Rossi, C ;
Sonke, GS ;
Floratos, DL ;
Kiemeney, LALM .
JOURNAL OF UROLOGY, 2002, 167 (04) :1734-1738
[10]   State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia [J].
Djavan, B ;
Chapple, C ;
Milani, S ;
Marberger, M .
UROLOGY, 2004, 64 (06) :1081-1088
123